These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 18056004

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [Abstract] [Full Text] [Related]

  • 6. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
    Pigneux A, Perreau V, Jourdan E, Vey N, Dastugue N, Huguet F, Sotto JJ, Salmi LR, Ifrah N, Reiffers J.
    Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
    Höglund M, Brune M, Sallerfors B, Ahlgren T, Billström R, Hedenus M, Markevärn B, Nilsson B, Simonsson B, Stockelberg D, Wahlin A.
    Bone Marrow Transplant; 2003 Dec; 32(12):1119-24. PubMed ID: 14647265
    [Abstract] [Full Text] [Related]

  • 9. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
    Candoni A, Simeone E, Tiribelli M, Malagola M, Russo D, Fanin R.
    Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
    [No Abstract] [Full Text] [Related]

  • 10. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
    Montillo M, Ricci F, Tedeschi A, Cafro AM, Nosari AM, Nichelatti M, Marbello L, Morra E.
    Leuk Res; 2009 Aug; 33(8):1072-8. PubMed ID: 19187960
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
    Olivieri A, Capelli D, Troiani E, Poloni A, Montanari M, Offidani M, Discepoli G, Leoni P.
    Exp Hematol; 2007 Jul; 35(7):1074-82. PubMed ID: 17588476
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG, Wang FX, Chen YX, Cao XM, He AL, Liu J, Ma XR, Zhao WH, Liu SH, Wang JL.
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
    Lambertenghi-Deliliers G, Annaloro C, Cortelezzi A, Cortellaro M, Della Volpe A, Maiolo AT, Mozzana R, Pogliani E, Pozzoli E, Polli EE.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC, Mandelli F.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
    Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A.
    BMC Cancer; 2008 Jul 10; 8():195. PubMed ID: 18616811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.